Drugs / PHIN-214
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05490888 | Jan 2022 → May 2026 overdue | cirrhosis of liver, fibrotic liver disease | PharmaIN | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-08 | PharmaIN | Results AASLD25 Poster Presentation: Phase 1, Single-Ascending Dose Results from the PHIN-001® Study of PHIN-214 in Compensated and Decompensated Patients with Cirrhosis. pharmain.com ↗
Phase 1, Single-Ascending Dose Results from the PHIN-001* Study of PHIN-214 in Compensated and Decompensated Patients with Cirrhosis. |
| 2025-11-08 | PharmaIN | Results PharmaIN Corporation Showcases Phase 1 Single-Ascending Dose Results from PHIN-001 Study of PHIN-214 in Patients with Compensated and Decompensated Cirrhosis at the AASLD, The Liver meeting® 2025 pharmain.com ↗
PharmaIN Corporation, a clinical-stage biopharmaceutical company, today unveiled promising early results from the single-ascending dose phase of its Phase 1 trial of PHIN-214, a potential outpatient therapy for managing portal hypertension and its complications in patients with cirrhosis. |
| 2024-11-18 | PharmaIN | Results PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD – The Liver Meeting® 2024 pharmain.com ↗
PharmaIN Corporation, a clinical-stage biopharmaceutical company dedicated to developing innovative subcutaneous peptide therapies, today introduced interim results from its ongoing Phase 1b clinical trial of PHIN-214 for the prevention and treatment of decompensated cirrhosis. |
| 2024-05-28 | PharmaIN | Results Biomedicine & Pharmacotherapy: Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist pharmain.com ↗
PHIN-214 enables once-daily subcutaneous administration without causing ischemia or tissue necrosis and has a 10-fold higher therapeutic index than terlipressin in healthy rats. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHIN-214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490888 ↗ |
| Action | Activate | “It is a partial V1a agonist” NCT05490888 ↗ |
| Route | Subcutaneous | “PHIN-214 is a terlipressin derivative administered subcutaneously.” NCT05490888 ↗ |